RSV Vaccine Sales Decline

This is a U.S. news story, published by Yahoo, that relates primarily to Pfizer news.

U.S. news

For more U.S. news, you can click here:

more U.S. news

Pfizer news

For more Pfizer news, you can click here:

more Pfizer news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Yahoo news

For more news from Yahoo, you can click here:

more news from Yahoo

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

Pfizer RSV shots

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest vaccine bookings news, RSV vaccinations news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

RSV vaccines

Reuters

•

Analysis-GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up

Summary

Nutrition label

81% Informative

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now.

Some independent pharmacists said demand during the vaccination season for respiratory syncytial virus shots has fallen as much as two-thirds from a year ago .

The shots are important for both Pfizer and GSK as they look to build new franchises before top-selling drugs face generic competition later this decade .

Moderna 's mResvia was approved in May , but the third entry to the market is expected to trail the other two because it was approved too late to get a share in the largest pharmacies, the company said. "It's not a flu shot," said BMO analyst Evan Seigerman . "These shots that you don't get over and over again, they're not an annuity." (Reporting by Michael Erman ; Editing by Caroline Humer and Bill Berkrot ).